AIM ImmunoTech Inc. (AIM): Nasdaq/NYSE listing notice — AIM ImmunoTech receives NYSE American delisting notice for stockholders' equity deficit

AIM ImmunoTech Inc.

Stockholders' deficit of $2.9M as of Sept 30, 2024; fails $4M and $6M equity thresholds.
Must submit compliance plan by Jan 10, 2025; cure period until June 11, 2026.
Stock to trade with ".BC" designation while below compliance; no immediate impact on listing.
Company has reported net losses in five most recent fiscal years.
If plan not accepted or compliance not regained, delisting proceedings may commence.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AIM ImmunoTech Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(ii), 1003(a)(iii)).

Exchange: nyse american
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 1003(a)(ii), 1003(a)(iii)

Exact text from the filing

losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of September 30, 2024, the Company had a stockholders’ deficit of $2.9 million and has had losses in the most recent five fiscal years ended December 31, 2023. The Company is now subject to the procedures and requirements of Section 1009 of the Company

View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

AIM ImmunoTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-050433

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.